Show simple item record

dc.contributor.authorClayton, Peter E
dc.contributor.authorShalet, Stephen M
dc.date.accessioned2009-08-06T15:03:38Z
dc.date.available2009-08-06T15:03:38Z
dc.date.issued2005
dc.identifier.citationDifficulties in patient management associated with the transition period. 2005, 64 Suppl 2:74-5 Horm. Res.en
dc.identifier.issn0301-0163
dc.identifier.pmid16286777
dc.identifier.doi10.1159/000087759
dc.identifier.urihttp://hdl.handle.net/10541/76573
dc.description.abstractThe European Society for Paediatric Endocrinology (ESPE) held a consensus workshop in Manchester, UK, in December 2003 to discuss issues relating to the care of growth hormone (GH)-treated patients in the transition from paediatric to adult life. Aspects under consideration included the definition of transition, the process of delivery of transitional care, the exact need to reassess pituitary status after completion of growth and puberty in teenagers who have received GH treatment during childhood, the most appropriate biochemical definition of severe GH deficiency (GHD) in the transitional period, and the factors influencing both the decision to reinstitute treatment and also the timing and dosage schedule when GH treatment is reinstituted.
dc.language.isoenen
dc.subject.meshAdolescent
dc.subject.meshAdolescent Health Services
dc.subject.meshAdult
dc.subject.meshContinuity of Patient Care
dc.subject.meshGrowth Disorders
dc.subject.meshHuman Growth Hormone
dc.subject.meshHumans
dc.subject.meshPuberty
dc.titleDifficulties in patient management associated with the transition period.en
dc.typeArticleen
dc.contributor.departmentEndocrine Science Research Group, Division of Human Development, The Medical School, University of Manchester, Manchester, UK. peter.clayton@manchester.ac.uken
dc.identifier.journalHormone Researchen
html.description.abstractThe European Society for Paediatric Endocrinology (ESPE) held a consensus workshop in Manchester, UK, in December 2003 to discuss issues relating to the care of growth hormone (GH)-treated patients in the transition from paediatric to adult life. Aspects under consideration included the definition of transition, the process of delivery of transitional care, the exact need to reassess pituitary status after completion of growth and puberty in teenagers who have received GH treatment during childhood, the most appropriate biochemical definition of severe GH deficiency (GHD) in the transitional period, and the factors influencing both the decision to reinstitute treatment and also the timing and dosage schedule when GH treatment is reinstituted.


This item appears in the following Collection(s)

Show simple item record